Grifols achieved its best score in the S&P Global Sustainability ranking with 70 points, improving by seven from last year. The ranking recognized its advancements in...
GigaGen will develop a recombinant polyclonal antibody therapy for botulinum neurotoxins and another biological threat. Grifols expects €930 million in U.S. revenues from Yimmugo, an immunoglobulin...
Rovi shares fell 10.5%, contributing to a 1.9% decline in Spain's pharmaceutical sector. Almirall also dropped 1.2%, while PharmaMar and Grifols rose 22.4% and 1.4%, respectively....
JPMorgan Chase reduced its stake in Grifols from 3.09% to 2.99% as Brookfield seeks sovereign fund partners for a potential takeover bid. JPMorgan's 12.7 million shares...
Grifols shares rose 2.6% following reports that Canadian firm Brookfield is in informal talks with sovereign funds for a takeover bid. Brookfield is seeking €9.5 billion...
JPMorgan Chase reduced its stake in Grifols to 3.111%, down from a previous 3.458%, with 0.256% in voting rights and 2.855% through financial instruments. This follows...
Moody's withdrew Grifols' ratings, citing "insufficient or inadequate" information amid a potential takeover by family shareholders and Brookfield fund. Grifols' shares dropped, with Class A down...
Grifols can modify its complaint until September 9 or notify by August 13 if it will maintain it. Gotham has until September 12 to respond, Grifols...
Biotest, a Grifols group company, expects $1 billion in US sales of its immunoglobulin drug Yimmugo over the next seven years, following FDA approval. Grifols shares...
Grifols and PharmaMar significantly dropped Spanish pharmaceutical stocks, with declines of 49.1% and 22.5% respectively in the first half of 2024. Although other companies like Rovi...